196 related articles for article (PubMed ID: 32401673)
1. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.
Kuebler WM; Jordt SE; Liedtke WB
Am J Physiol Lung Cell Mol Physiol; 2020 Jun; 318(6):L1239-L1243. PubMed ID: 32401673
[TBL] [Abstract][Full Text] [Related]
2. COVID-19: urgent reconsideration of lung edema as a preventable outcome Inhibition of TRPV4 as a promising and feasible approach.
Kuebler WM; Jordt SE; Liedtke WB
SSRN; 2020 Mar; ():3558887. PubMed ID: 32714108
[TBL] [Abstract][Full Text] [Related]
3. Endothelial TRPV4 channels in lung edema and injury.
Sonkusare SK; Laubach VE
Curr Top Membr; 2022; 89():43-62. PubMed ID: 36210151
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and In Vitro Experimental Validation of Novel TRPV4 Antagonists Inspired by Labdane Diterpenes.
Mazzotta S; Carullo G; Schiano Moriello A; Amodeo P; Di Marzo V; Vega-Holm M; Vitale RM; Aiello F; Brizzi A; De Petrocellis L
Mar Drugs; 2020 Oct; 18(10):. PubMed ID: 33081023
[TBL] [Abstract][Full Text] [Related]
5. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.
Thorneloe KS; Cheung M; Bao W; Alsaid H; Lenhard S; Jian MY; Costell M; Maniscalco-Hauk K; Krawiec JA; Olzinski A; Gordon E; Lozinskaya I; Elefante L; Qin P; Matasic DS; James C; Tunstead J; Donovan B; Kallal L; Waszkiewicz A; Vaidya K; Davenport EA; Larkin J; Burgert M; Casillas LN; Marquis RW; Ye G; Eidam HS; Goodman KB; Toomey JR; Roethke TJ; Jucker BM; Schnackenberg CG; Townsley MI; Lepore JJ; Willette RN
Sci Transl Med; 2012 Nov; 4(159):159ra148. PubMed ID: 23136043
[TBL] [Abstract][Full Text] [Related]
6. Prevention of ventilator-induced lung edema by inhalation of nanoparticles releasing ruthenium red.
Jurek SC; Hirano-Kobayashi M; Chiang H; Kohane DS; Matthews BD
Am J Respir Cell Mol Biol; 2014 Jun; 50(6):1107-17. PubMed ID: 24405281
[TBL] [Abstract][Full Text] [Related]
7. Role of Transient Receptor Potential Vanilloid 4 in Neutrophil Activation and Acute Lung Injury.
Yin J; Michalick L; Tang C; Tabuchi A; Goldenberg N; Dan Q; Awwad K; Wang L; Erfinanda L; Nouailles G; Witzenrath M; Vogelzang A; Lv L; Lee WL; Zhang H; Rotstein O; Kapus A; Szaszi K; Fleming I; Liedtke WB; Kuppe H; Kuebler WM
Am J Respir Cell Mol Biol; 2016 Mar; 54(3):370-83. PubMed ID: 26222277
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
9. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
10. TRPV4 initiates the acute calcium-dependent permeability increase during ventilator-induced lung injury in isolated mouse lungs.
Hamanaka K; Jian MY; Weber DS; Alvarez DF; Townsley MI; Al-Mehdi AB; King JA; Liedtke W; Parker JC
Am J Physiol Lung Cell Mol Physiol; 2007 Oct; 293(4):L923-32. PubMed ID: 17660328
[TBL] [Abstract][Full Text] [Related]
11. TRPV4 inhibition attenuates stretch-induced inflammatory cellular responses and lung barrier dysfunction during mechanical ventilation.
Pairet N; Mang S; Fois G; Keck M; Kühnbach M; Gindele J; Frick M; Dietl P; Lamb DJ
PLoS One; 2018; 13(4):e0196055. PubMed ID: 29664963
[TBL] [Abstract][Full Text] [Related]
12. Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis.
Calender A; Israel-Biet D; Valeyre D; Pacheco Y
Trends Immunol; 2020 Oct; 41(10):856-859. PubMed ID: 32863134
[TBL] [Abstract][Full Text] [Related]
13. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
14. Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury.
Guo J; Wei X; Li Q; Li L; Yang Z; Shi Y; Qin Y; Zhang X; Wang X; Zhi X; Meng D
J Cell Physiol; 2020 Dec; 235(12):9884-9894. PubMed ID: 32510598
[TBL] [Abstract][Full Text] [Related]
15. Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Roehrig S; Ait Hssain A; Shallik NAH; Elsaid IMA; Mustafa SF; Smain OAM; Molokhia AA; Lance MD
Trials; 2020 Sep; 21(1):781. PubMed ID: 32917259
[TBL] [Abstract][Full Text] [Related]
16. TRPV4: an exciting new target to promote alveolocapillary barrier function.
Morty RE; Kuebler WM
Am J Physiol Lung Cell Mol Physiol; 2014 Dec; 307(11):L817-21. PubMed ID: 25281637
[TBL] [Abstract][Full Text] [Related]
17. The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients.
Yashavantha Rao HC; Jayabaskaran C
J Med Virol; 2020 Jul; 92(7):786-790. PubMed ID: 32320066
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].
Zhang T; Sun LX; Feng RE
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jun; 43(6):496-502. PubMed ID: 32241072
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and Respiratory System Disorders: Current Knowledge, Future Clinical and Translational Research Questions.
Brosnahan SB; Jonkman AH; Kugler MC; Munger JS; Kaufman DA
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2586-2597. PubMed ID: 32960072
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two methods to clear the airways of critically ill children and adults with COVID-19 infection: a structured summary of a study protocol for a pilot randomized controlled trial.
Kawaguchi A; Bernier G; Lacroix J; El Salti S; Cheng MP; Lee TC; Khwaja K; Jouvet P
Trials; 2020 Jul; 21(1):610. PubMed ID: 32620174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
